Enterisol lleitis lyophilisate and diluent for oral suspension for pigs

Authorised

• Lawsonia intracellularis, strain MS B3903, Live

Product identification

Medicine name:

Enterisol lleitis lyophilisate and diluent for oral suspension for pigs Enterisol lleitis

Active substance:

Lawsonia intracellularis, strain MS B3903, Live

Target species:

Pig

Route of administration:

Oral use

Product details

Active substance and strength:

Lawsonia intracellularis, strain MS B3903, Live 79433.00 tissue culture infective dose 50 / 1.00 Dose

Pharmaceutical form:

Lyophilisate and solvent for oral suspension

Withdrawal period by route of administration: Oral use:

Pig

- Meat and offal. no withdrawal period Withdrawal period is 0 days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

Q109AE04

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Germany

Package description:

(ID8): 1 Box with 12 Box with (1 Bottle (Glass) with 100 Dose and 1 Bottle (High Density PolyEthylene) with 200 millilitre(s)) (1200.0 Dose, 2400.0 millilitre(s))

(ID6): 1 Box with (1 Bottle (Glass) with 100 Dose and 1 Bottle (High Density

PolyEthylene) with 200 millilitre(s)) (100.0 Dose, 200.0 millilitre(s))

(ID4): 1 Box with (1 Bottle (Glass) with 50 Dose and 1 Bottle (High Density

PolyEthylene) with 100 millilitre(s)) (50.0 Dose, 100.0 millilitre(s))

(ID2): 1 Box with (1 Bottle (Glass) with 10 Dose and 1 Bottle (High Density PolyEthylene) with 20 millilitre(s)) (10.0 Dose, 20.0 millilitre(s))

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

Marketing authorisation holder:

Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:

28/10/2004

Manufacturing sites for batch release:

Boehringer Ingelheim Vetmedica GmbH

Responsible authority:

Paul-Ehrlich-Institut

Authorisation number:

PEI.V.02996.01.1

Date of authorisation status change:

5/11/2009

Reference member state:

Germany

Procedure number:

DE/V/0236/001

Concerned member states:

Austria Belgium Bulgaria Cyprus Czechia Denmark Estonia Finland France Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)

Published on: 14/02/2022

Download

Source URL: https://medicines.health.europa.eu/veterinary/600000063054